Posted by Michael Wonder on 19 Jun 2024
European Commission grants Sobi marketing authorisation for Altuvoct for treatment of haemophilia A
19 June 2024 - Sobi today announced the European Commission has granted marketing authorisation for Altuvoct's (efanesoctocog alfa), for the treatment and prevention of bleeds and peri-operative prophylaxis in haemophilia A.
The European Commission also endorsed the EMA recommendation supporting Altuvoct's retention of orphan drug designation, granting a 10 year market exclusivity period.
